SetPoint intends to offer patients and providers a better alternative for the treatment of chronic inflammatory diseases with less risk and lower cost than drug therapy. SetPoint believes neuromodulation for the treatment of rheumatoid arthritis and other inflammatory diseases will be ground-breaking for patients, physicians and payors:
The SetPoint Platform
- For patients, the implanted microregulator is intended to last 10 years, freeing them from routine injections or pills and the risks and substantial cost associated with current treatments.
- For physicians, the device is designed to provide a novel and less expensive alternative for patients suffering from RA.
- For payors, the device may improve the lives of those suffering from RA, while decreasing costs by up to 75%.
CAUTION: Investigational device in the US and the European Union. Limited by country law to investigational use only.